Want to see MRKR full AI Analyst Report?
MRKR Stock Chart & Stats
$1.66
-$0.17(-5.70%)
At close: 4:00 PM EST
$1.66
-$0.17(-5.70%)
Day’s Range― - ―
52-Week Range$0.81 - $2.46
Previous CloseN/A
Volume39.59K
Average Volume (3M)62.00K
Market Cap
$21.84M
Enterprise Value$9.47
Total Cash (Recent Filing)$14.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 19, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding16,673,126
10 Day Avg. Volume79,446
30 Day Avg. Volume61,996
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.36
Price to Sales (P/S)0.00
P/FCF Ratio-1.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside442.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$2.73M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No Reported DebtBalance-sheet leverage is effectively nil across recent periods, removing interest burden and lowering bankruptcy risk. For a clinical-stage biotech this durable low-debt profile preserves strategic optionality to fund trials, pursue partnerships, or raise capital without heavy fixed-interest costs.
Proprietary MultiTAA T‑cell PlatformMarker’s MultiTAA T‑cell platform targets multiple tumor antigens, a durable competitive asset enabling addressable breadth across hematologic and solid tumors. Such a platform can support multiple programs, licensing or partnerships and provides long-term R&D optionality beyond any single candidate's outcome.
Greater Capital-raising FlexibilityThe authorized share increase is a structural corporate change that expands the board’s ability to raise equity, fund clinical development, or execute transactions. This durable enhancement to capital structure optionality improves ability to sustain R&D programs through future financing or deals.
Bears Say
Negative Gross Profit & Large Net LossesPersistent negative gross margins indicate the core development activities are not yet scalable to profitable operations. Large recurring net losses erode equity and require continual capital; until programs advance toward commercial-stage economics, profitability remains structurally distant.
Persistent Operating Cash BurnOperating cash flow has been durably negative, reflecting ongoing funding of trials and R&D. Chronic cash burn forces reliance on external financing, which can dilute shareholders or constrain strategic choices, and creates persistent execution risk if capital markets tighten or terms deteriorate.
Very Small Operating ScaleA tiny headcount and low, declining revenue base limit internal capacity to run multiple clinical programs or commercial efforts. Sustained growth will require material external investment or partnerships; operational scale constraints are a persistent hurdle to executing and commercializing therapies.
Marker Therapeutics News
MRKR FAQ
What was Marker Therapeutics’s price range in the past 12 months?
Marker Therapeutics lowest stock price was $0.81 and its highest was $2.46 in the past 12 months.
What is Marker Therapeutics’s market cap?
Marker Therapeutics’s market cap is $21.84M.
When is Marker Therapeutics’s upcoming earnings report date?
Marker Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were Marker Therapeutics’s earnings last quarter?
Marker Therapeutics released its earnings results on May 20, 2026. The company reported -$0.16 earnings per share for the quarter, the consensus estimate of -$0.16 by $0.
Is Marker Therapeutics overvalued?
According to Wall Street analysts Marker Therapeutics’s price is currently Undervalued.
Does Marker Therapeutics pay dividends?
Marker Therapeutics does not currently pay dividends.
What is Marker Therapeutics’s EPS estimate?
Marker Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Marker Therapeutics have?
Marker Therapeutics has 16,673,126 shares outstanding.
What happened to Marker Therapeutics’s price movement after its last earnings report?
Marker Therapeutics reported an EPS of -$0.16 in its last earnings report, expectations of -$0.16. Following the earnings report the stock price went up 1.439%.
Which hedge fund is a major shareholder of Marker Therapeutics?
Currently, no hedge funds are holding shares in MRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
MRKR Stock 12 Month Forecast
Average Price Target
$9.00
▲(442.17% Upside)
Technical Analysis
Ibio
―
Moleculin Biotech
―
ABVC BioPharma
―
Addex Therapeutics
―
Allarity Therapeutics
―
Ownership Overview
18.09%
Insiders
3.00% Mutual Funds
<0.01% Other Institutional Investors
76.35% Public Companies and
Individual Investors